

BECTON DICKINSON & CO  
Form 8-K  
December 19, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report (Date of earliest event reported): December 19, 2014**

**BECTON, DICKINSON AND COMPANY**  
**(Exact name of registrant as specified in its charter)**

**New Jersey**  
**(State or Other Jurisdiction**  
**of Incorporation)**

**001-4802**  
**(Commission File**  
**Number)**  
**1 Becton Drive**

**22-0760120**  
**(I.R.S. Employer**  
**Identification No.)**

Edgar Filing: BECTON DICKINSON & CO - Form 8-K

**Franklin Lakes, New Jersey 07147-1880**

**(Address of Principal Executive Offices including Zip Code)**

**(201) 847-6800**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01. Entry into a Material Definitive Agreement.**

On December 19, 2014, Becton, Dickinson and Company (NYSE:BDX) (BD) entered into a 364-day term loan agreement (the Term Loan Agreement), by and among BD, as borrower, Goldman Sachs Bank USA, as administrative agent (the Administrative Agent) and the lenders party thereto that provides for a \$1.0 billion term loan facility (the Term Loan Facility). Proceeds of the Term Loan Facility may be used only to pay for (i) a portion of the cash consideration due in connection with BD's previously announced and currently pending acquisition of CareFusion Corporation, a Delaware corporation (CareFusion), pursuant to an agreement and plan of merger, dated October 5, 2014, by and among BD, CareFusion and Griffin Sub, Inc., a Delaware corporation and wholly owned subsidiary of BD (the Merger) and the financing transactions associated with the Merger (together with the Merger, the Transactions) and (ii) the fees and expenses associated with the Transactions.

As previously announced, BD plans to consummate the Merger using cash on hand, borrowings under BD's commercial paper program and permanent financing. BD currently expects that such permanent financing will consist of a combination of (i) the Term Loan Facility, (ii) the net cash proceeds of the senior unsecured notes (the Notes) issued by BD on December 15, 2014 and (iii) to the extent required, borrowings under the 364-day bridge term loan agreement, dated as of November 14, 2014, by and among BD, as borrower, Goldman Sachs Bank USA, as administrative agent and the lenders party thereto (the Bridge Loan Agreement), the commitments of which have been reduced by the net cash proceeds of the Notes and the commitments under the Term Loan Facility as well as by a voluntary reduction of \$536,125,000.

Under the Term Loan Agreement, Goldman Sachs Bank USA will act as administrative agent; Goldman Sachs Bank USA and J.P. Morgan Securities LLC will act as joint lead arrangers and joint bookrunners; JPMorgan Chase Bank, N.A. will act as syndication agent; and The Bank of Tokyo-Mitsubishi UFJ, Ltd., BNP Paribas, The Bank of New York Mellon, Citibank, N.A. and Morgan Stanley Senior Funding, Inc. will act as documentation agents.

The Term Loan Facility will be unsecured. The loans under the Term Loan Facility will have an interest rate equal to either the Eurodollar rate, plus a margin of 100 to 175 basis points, or a base rate, plus a margin of 0 to 75 basis points. The applicable margin will be determined based on the credit ratings of BD's then-current long-term senior unsecured, unguaranteed debt securities.

The covenants in the Term Loan Agreement are the same as those in our Bridge Loan Agreement. The financial covenants in the Term Loan Agreement require BD to have (i) a ratio of consolidated EBITDA (as defined in the Term Loan Agreement) to interest expense of not less than 5.00:1.00 as of the last day of each fiscal quarter and (ii) a ratio of Debt (as defined in the Term Loan Agreement) to EBITDA of no more than 4.75:1:00 as of the last day of each fiscal quarter following the closing of the Term Loan Facility. The Term Loan Agreement also contains covenants that restrict BD in respect of, among other things, mergers and consolidations, sales of all or substantially all assets, incurrence of liens, change in nature of business and transactions with affiliates. The Term Loan Agreement is subject to acceleration upon the occurrence of an event of default, including cross-default with regard to indebtedness of BD or its subsidiaries in excess of \$200 million in the aggregate; failure to make a payment on other indebtedness of BD or its subsidiaries in an aggregate principal outstanding amount of at least \$25 million; change of control (as defined in the Term Loan Agreement); entry of judgment or order to pay of \$25 million or more which is not stayed; the occurrence of certain Employee Retirement Income Security Act of 1974 or bankruptcy events; failure to make payments under the Term Loan Facility when due; breach of representations and warranties or covenants under the Term Loan Facility; and invalidity of loan documents.

Borrowing under the Term Loan Agreement is subject to certain conditions precedent, including, among other conditions, the consummation of the Merger in accordance with the Merger Agreement; the absence since June 30, 2014 of undisclosed CareFusion material adverse effects (as defined in the Term Loan Agreement); the delivery of certain information, including financial information, to the Administrative Agent; the accuracy of certain representations and warranties; and the absence of certain defaults or events of default. The loans under the Term Loan Facility will be due and payable within one year of borrowing.

The descriptions of the provisions of the Term Loan Agreement are summary in nature and are qualified in their entirety by reference to the full and complete terms of the Term Loan Agreement, which is filed herewith as Exhibit 10.1.

Some of the agents and lenders under the Term Loan Agreement and certain of their affiliates have engaged, and in the future may engage, in investment banking transactions, including securities offerings, and in general financing and commercial banking transactions with, and the provision of services to, BD and its affiliates in the ordinary course of business and otherwise for which they have received, and will in the future receive, customary fees.

**Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The disclosure of the material terms and conditions of the Term Loan Agreement contained in Item 1.01 above is hereby incorporated into this Item 2.03 by reference.

**Item 9.01. Financial Statements and Exhibits.**

| EXHIBIT NO. | DESCRIPTION OF DOCUMENT   |
|-------------|---|
| 10.1*       | 364-Day Term Loan Agreement, dated December 19, 2014, by and among Becton, Dickinson and Company, as borrower, Goldman Sachs Bank USA, as administrative agent, and the lenders party thereto |

\* Filed herewith.

***Forward-Looking Statements***

*This communication contains certain estimates and other forward-looking statements (as defined under Federal securities laws). Forward looking statements generally are accompanied by words such as will, expect, outlook or other similar words, phrases or expressions. These forward-looking statements include statements regarding the estimated or anticipated future results of BD, and of the combined company following BD's proposed acquisition of CareFusion, the anticipated benefits of the proposed combination, including estimated synergies, the expected timing of completion of the transaction and other statements that are not historical facts. These statements are based on the current expectations of BD and CareFusion management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties regarding BD and CareFusion's respective businesses and the proposed acquisition, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the ability of the parties to successfully close the proposed acquisition, including the risk that the required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the transaction; risks relating*

*to the integration of CareFusion's operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; the outcome of any legal proceedings related to the proposed merger; access to available financing for the refinancing of BD's or CareFusion's debt on a timely basis and reasonable terms; the ability to market and sell CareFusion's products in new markets, including the ability to obtain necessary regulatory product registrations and clearances; the loss of key senior management or other associates; the anticipated demand for BD's and CareFusion's products, including the risk of future reductions in government healthcare funding, changes in reimbursement rates or changes in healthcare practices that could result in lower utilization rates or pricing pressures; the impact of competition in the medical device industry; the risks of fluctuations in interest or foreign currency exchange rates; product liability claims; difficulties inherent in product development, including the timing or outcome of product development efforts, the ability to obtain regulatory approvals and clearances and the timing and market success of product launches; risks relating to fluctuations in the cost and availability of raw materials and other sourced products and the ability to maintain favorable supplier arrangements and relationships; successful compliance with governmental regulations applicable to BD, CareFusion and the combined company; changes in regional, national or foreign economic conditions; uncertainties of litigation, as well as other factors discussed in BD's and CareFusion's respective filings with the Securities Exchange Commission (SEC). BD and CareFusion do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.*

### **IMPORTANT INFORMATION FOR INVESTORS**

*In connection with the proposed transaction, on December 16, 2014, BD filed with the SEC amendment no. 1 to the registration statement on Form S-4 that included a preliminary prospectus of BD and that also constitutes a preliminary proxy statement of CareFusion. The registration statement has been declared effective by the SEC, and the definitive proxy statement/prospectus is being delivered to stockholders of CareFusion. BD and CareFusion also plan to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE MERGER THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the registration statement and the definitive proxy statement/prospectus and other relevant documents filed by BD and CareFusion with the SEC at the SEC's website at [www.sec.gov](http://www.sec.gov). In addition, you will be able to obtain free copies of these documents by phone, e-mail or written request by contacting the investor relations department of BD or CareFusion at the following: Monique N. Dolecki, Investor Relations 201-847-5378 [Monique\\_Dolecki@bd.com](mailto:Monique_Dolecki@bd.com) or Jim Mazzola, Investor Relations 858-617-1203 [Jim.Mazzola@CareFusion.com](mailto:Jim.Mazzola@CareFusion.com)*

### **PARTICIPANTS IN THE SOLICITATION**

*BD and CareFusion and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about BD's directors and executive officers is available in BD's proxy statement dated December 19, 2013, for its 2014 Annual Meeting of Shareholders and subsequent SEC filings. Information about CareFusion's directors and executive officers is available in CareFusion's proxy statement dated September 25, 2014, for its 2014 Annual Meeting of Stockholders. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the merger when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from BD or CareFusion as indicated above. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.*

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BECTON, DICKINSON AND  
COMPANY**

By /s/ Gary DeFazio  
Gary DeFazio  
Vice President and Corporate Secretary

Date: December 19, 2014

Index to Exhibits

| EXHIBIT NO. | DESCRIPTION OF DOCUMENT   |
|-------------|---|
| 10.1*       | 364-Day Term Loan Agreement, dated December 19, 2014, by and among Becton, Dickinson and Company, as borrower, Goldman Sachs Bank USA, as administrative agent, and the lenders party thereto |

\* Filed herewith.